Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GC4711 with SBRT for NSCLC
NCT04476797Phase 2Terminated
- Sponsor
- Galera Therapeutics, Inc.
- Start
- Oct 2020
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rucosopasem manganese in non-small cell lung cancer (NSCLC), sponsored by Galera Therapeutics, Inc.. Started Oct 2020; status: terminated.
02
Drugs
rucosopasem manganese
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04476797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04476797.